메뉴 건너뛰기




Volumn 10, Issue 1, 2012, Pages 21-30

Nevirapine extended-release for the treatment of HIV-1 infection

Author keywords

antiretroviral therapy; extended release; HIV; nevirapine

Indexed keywords

ATAZANAVIR; ATAZANAVIR PLUS RITONAVIR; EFAVIRENZ; EFAVIRENZ PLUS EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; EMTRICITABINE; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; NEVIRAPINE; RILPIVIRINE; TENOFOVIR;

EID: 83455244422     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/eri.11.145     Document Type: Article
Times cited : (5)

References (55)
  • 1
    • 0025679303 scopus 로고
    • Inhibition of HIV-1 replication by a nonnucleoside reverse transcriptase inhibitor
    • Merluzzi VJ, Hargrave KD, Labadia M, et al. Inhibition of HIV-1 replication by a nonnucleoside reverse transcriptase inhibitor. Science 250(4986), 1411-1413 (1990).
    • (1990) Science , vol.250 , Issue.4986 , pp. 1411-1413
    • Merluzzi, V.J.1    Hargrave, K.D.2    Labadia, M.3
  • 2
    • 0026607918 scopus 로고
    • Nonnucleoside inhibitors of HIV-1 reverse transcriptase: Nevirapine as a prototype drug
    • Grob PM, Wu JC, Cohen KA, et al. Nonnucleoside inhibitors of HIV-1 reverse transcriptase: nevirapine as a prototype drug. AIDS Res. Hum. Retrovir. 8(2), 145-152 (1992).
    • (1992) AIDS Res. Hum. Retrovir. , vol.8 , Issue.2 , pp. 145-152
    • Grob, P.M.1    Wu, J.C.2    Cohen, K.A.3
  • 3
    • 0026586356 scopus 로고
    • Inhibition of HIV-1 reverse transcriptase and virus replication by a non-nucleoside dipyridodiazepinone BI-RG-587 (Nevirapine)
    • Skoog MT, Hargrave KD, Miglietta JJ, Kopp EB, Merluzzi VJ. Inhibition of HIV-1 reverse transcriptase and virus replication by a non-nucleoside dipyridodiazepinone BI-RG-587 (Nevirapine). Med. Res. Rev. 12(1), 27-40 (1992).
    • (1992) Med. Res. Rev. , vol.12 , Issue.1 , pp. 27-40
    • Skoog, M.T.1    Hargrave, K.D.2    Miglietta, J.J.3    Kopp, E.B.4    Merluzzi, V.J.5
  • 4
    • 0028900894 scopus 로고
    • Phase 1/2 evaluation of nevirapine alone and in combination with zidovudine for infection with human immunodeficiency virus
    • Cheeseman SH, Havlir D, McLaughlin MM, et al. Phase 1/2 evaluation of nevirapine alone and in combination with zidovudine for infection with human immunodeficiency virus. J. Acquir. Immu. Defic. Syndr. Hum. Retrovirol. 8(2), 141-151 (1995).
    • (1995) J. Acquir. Immu. Defic. Syndr. Hum. Retrovirol. , vol.8 , Issue.2 , pp. 141-151
    • Cheeseman, S.H.1    Havlir, D.2    McLaughlin, M.M.3
  • 5
    • 0032565098 scopus 로고    scopus 로고
    • A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: The INCAS Trial. Italy, the Netherlands, Canada and Australia Study
    • Montaner JS, Reiss P, Cooper D, et al. A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS Trial. Italy, The Netherlands, Canada and Australia Study. JAMA 279(12), 930-937 (1998).
    • (1998) JAMA , vol.279 , Issue.12 , pp. 930-937
    • Montaner, J.S.1    Reiss, P.2    Cooper, D.3
  • 6
    • 0035195146 scopus 로고    scopus 로고
    • The role of nevirapine in the treatment of HIV-1 disease
    • Podzamczer D, Fumero E. The role of nevirapine in the treatment of HIV-1 disease. Exp. Opin. Pharmacother. 2(12), 2065-2078 (2001).
    • (2001) Exp. Opin. Pharmacother. , vol.2 , Issue.12 , pp. 2065-2078
    • Podzamczer, D.1    Fumero, E.2
  • 7
    • 0036592078 scopus 로고    scopus 로고
    • A randomized clinical trial comparing nelfinavir or nevirapine associated to zidovudine/lamivudine in HIV-infected naive patients (the Combine Study)
    • Podzamczer D, Ferrer E, Consiglio E, et al. A randomized clinical trial comparing nelfinavir or nevirapine associated to zidovudine/lamivudine in HIV-infected naive patients (the Combine Study). Antivir. Ther. 7(2), 81-90 (2002).
    • (2002) Antivir. Ther. , vol.7 , Issue.2 , pp. 81-90
    • Podzamczer, D.1    Ferrer, E.2    Consiglio, E.3
  • 9
    • 33646034630 scopus 로고    scopus 로고
    • Adherence-resistance relationships for protease and non-nucleoside reverse transcriptase inhibitors explained by virological fitness
    • Bangsberg DR, Acosta EP, Gupta R, et al. Adherence-resistance relationships for protease and non-nucleoside reverse transcriptase inhibitors explained by virological fitness. AIDS 20(2), 223-231 (2006).
    • (2006) AIDS , vol.20 , Issue.2 , pp. 223-231
    • Bangsberg, D.R.1    Acosta, E.P.2    Gupta, R.3
  • 10
    • 65449153627 scopus 로고    scopus 로고
    • The combined effect of modern highly active antiretroviral therapy regimens and adherence on mortality over time
    • Lima VD, Harrigan R, Bangsberg DR, et al. The combined effect of modern highly active antiretroviral therapy regimens and adherence on mortality over time. J. Acquir. Immu. Defic. Syndr. 50(5), 529-536 (2009).
    • (2009) J. Acquir. Immu. Defic. Syndr. , vol.50 , Issue.5 , pp. 529-536
    • Lima, V.D.1    Harrigan, R.2    Bangsberg, D.R.3
  • 11
    • 78650230394 scopus 로고    scopus 로고
    • Risk of viral failure declines with duration of suppression on highly active antiretroviral therapy irrespective of adherence level
    • Lima VD, Bangsberg DR, Harrigan PR, et al. Risk of viral failure declines with duration of suppression on highly active antiretroviral therapy irrespective of adherence level. J. Acquir. Immu. Defic. Syndr. 55(4), 460-465 (2010).
    • (2010) J. Acquir. Immu. Defic. Syndr. , vol.55 , Issue.4 , pp. 460-465
    • Lima, V.D.1    Bangsberg, D.R.2    Harrigan, P.R.3
  • 12
    • 0032808202 scopus 로고    scopus 로고
    • The value of patient-reported adherence to antiretroviral therapy in predicting virologic and immunologic response. California Collaborative Treatment Group
    • Haubrich RH, Little SJ, Currier JS, et al. The value of patient-reported adherence to antiretroviral therapy in predicting virologic and immunologic response. California Collaborative Treatment Group. AIDS 13(9), 1099-1107 (1999).
    • (1999) AIDS , vol.13 , Issue.9 , pp. 1099-1107
    • Haubrich, R.H.1    Little, S.J.2    Currier, J.S.3
  • 13
    • 0037090271 scopus 로고    scopus 로고
    • The consistency of adherence to antiretroviral therapy predicts biologic outcomes for human immunodeficiency virus-infected persons in clinical trials
    • Mannheimer S, Friedland G, Matts J, Child C, Chesney M. The consistency of adherence to antiretroviral therapy predicts biologic outcomes for human immunodeficiency virus-infected persons in clinical trials. Clin. Infect. Dis. 34(8), 1115-1121 (2002).
    • (2002) Clin. Infect. Dis. , vol.34 , Issue.8 , pp. 1115-1121
    • Mannheimer, S.1    Friedland, G.2    Matts, J.3    Child, C.4    Chesney, M.5
  • 15
    • 0036615658 scopus 로고    scopus 로고
    • Adherence to antiretroviral therapy and outcomes in HIV-infected patients enrolled in an induction/maintenance randomized trial
    • Flandre P, Peytavin G, Meiffredy V, et al. Adherence to antiretroviral therapy and outcomes in HIV-infected patients enrolled in an induction/maintenance randomized trial. Antivir. Ther. 7(2), 113-121 (2002).
    • (2002) Antivir. Ther. , vol.7 , Issue.2 , pp. 113-121
    • Flandre, P.1    Peytavin, G.2    Meiffredy, V.3
  • 16
    • 3042688704 scopus 로고    scopus 로고
    • Impact of once-and twice-daily dosing regimens on adherence and overall safety
    • Hawkins T. Impact of once-and twice-daily dosing regimens on adherence and overall safety. AIDS Read. 14(6), 320-334 (2004).
    • (2004) AIDS Read. , vol.14 , Issue.6 , pp. 320-334
    • Hawkins, T.1
  • 17
    • 67449118544 scopus 로고    scopus 로고
    • National cohort outcomes audit of patients commencing antiretrovirals from naive
    • British HIV Association (BHIVA)
    • Street E, Curtis H, Sabin CA, Monteiro EF, Johnson MA. British HIV Association (BHIVA) national cohort outcomes audit of patients commencing antiretrovirals from naive. HIV Med. 10(6), 337-342 (2009).
    • (2009) HIV Med. , vol.10 , Issue.6 , pp. 337-342
    • Street, E.1    Curtis, H.2    Sabin, C.A.3    Monteiro, E.F.4    Johnson, M.A.5
  • 18
    • 41349117196 scopus 로고    scopus 로고
    • Efficacy and safety of once-daily regimens in the treatment of HIV infection
    • Molina JM. Efficacy and safety of once-daily regimens in the treatment of HIV infection. Drugs 68(5), 567-578 (2008).
    • (2008) Drugs , vol.68 , Issue.5 , pp. 567-578
    • Molina, J.M.1
  • 19
    • 11144357656 scopus 로고    scopus 로고
    • Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: A randomised open-label trial, the 2NN Study
    • van Leth F, Phanuphak P, Ruxrungtham K, et al. Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study. Lancet 363(9417), 1253-1263 (2004).
    • (2004) Lancet , vol.363 , Issue.9417 , pp. 1253-1263
    • Van Leth, F.1    Phanuphak, P.2    Ruxrungtham, K.3
  • 20
    • 14744289438 scopus 로고    scopus 로고
    • Plasma HIV-1 RNA decline within the first two weeks of treatment is comparable for nevirapine, efavirenz, or both drugs combined and is not predictive of long-term virologic efficacy: A 2NN substudy
    • van Leth F, Huisamen CB, Badaro R, et al. Plasma HIV-1 RNA decline within the first two weeks of treatment is comparable for nevirapine, efavirenz, or both drugs combined and is not predictive of long-term virologic efficacy: a 2NN substudy. J. Acquir. Immu. Defic. Syndr. 38(3), 296-300 (2005).
    • (2005) J. Acquir. Immu. Defic. Syndr. , vol.38 , Issue.3 , pp. 296-300
    • Van Leth, F.1    Huisamen, C.B.2    Badaro, R.3
  • 21
    • 29744439524 scopus 로고    scopus 로고
    • Pharmacokinetics of nevirapine: Once-daily versus twice-daily dosing in the 2NN study
    • Kappelhoff BS, Huitema AD, van LF, et al. Pharmacokinetics of nevirapine: once-daily versus twice-daily dosing in the 2NN study. HIV Clin. Trials 6(5), 254-261 (2005).
    • (2005) HIV Clin. Trials , vol.6 , Issue.5 , pp. 254-261
    • Kappelhoff, B.S.1    Huitema, A.D.2    Van, L.F.3
  • 23
    • 77953915265 scopus 로고    scopus 로고
    • Early virological and immunological response is comparable for nevirapine and RTV-boosted atazanavir: An ARTEN sub-analysis
    • San Francisco CA USA, September 12-15 Abstract H-924c
    • Johnson M, Soriano V, Brockmeyer N, et al. Early virological and immunological response is comparable for nevirapine and RTV-boosted atazanavir: an ARTEN sub-analysis. Presented at: 49th ICAAC (Interscience Conference on Antimicrobial Agents and Chemotherapy). San Francisco, CA, USA, September 12-15 2009 (Abstract H-924c).
    • (2009) 49th ICAAC (Interscience Conference on Antimicrobial Agents and Chemotherapy)
    • Johnson, M.1    Soriano, V.2    Brockmeyer, N.3
  • 24
    • 0038369913 scopus 로고    scopus 로고
    • A randomized trial to study first-line combination therapy with or without a protease inhibitor in HIV-1-infected patients
    • van Leeuwen R, Katlama C, Murphy RL, et al. A randomized trial to study first-line combination therapy with or without a protease inhibitor in HIV-1-infected patients. AIDS 17(7), 987-999 (2003).
    • (2003) AIDS , vol.17 , Issue.7 , pp. 987-999
    • Van Leeuwen, R.1    Katlama, C.2    Murphy, R.L.3
  • 25
    • 0033748196 scopus 로고    scopus 로고
    • Comparison of twice-daily stavudine plus once-or twice-daily didanosine and nevirapine in early stages of HIV infection: The scan study
    • Garcia F, Knobel H, Sambeat MA, et al. Comparison of twice-daily stavudine plus once-or twice-daily didanosine and nevirapine in early stages of HIV infection: the scan study. AIDS 14(16), 2485-2494 (2000).
    • (2000) AIDS , vol.14 , Issue.16 , pp. 2485-2494
    • Garcia, F.1    Knobel, H.2    Sambeat, M.A.3
  • 26
    • 0034541548 scopus 로고    scopus 로고
    • The VIRGO study: Nevirapine, didanosine and stavudine combination therapy in antiretroviral-naive HIV-1-infected adults
    • Raffi F, Reliquet V, Ferre V, et al. The VIRGO study: nevirapine, didanosine and stavudine combination therapy in antiretroviral-naive HIV-1-infected adults. Antivir. Ther. 5(4), 267-272 (2000).
    • (2000) Antivir. Ther. , vol.5 , Issue.4 , pp. 267-272
    • Raffi, F.1    Reliquet, V.2    Ferre, V.3
  • 27
    • 0034115801 scopus 로고    scopus 로고
    • The steady-state pharmacokinetics of nevirapine during once daily and twice daily dosing in HIV-1-infected individuals
    • van Heeswijk RP, Veldkamp AI, Mulder JW, et al. The steady-state pharmacokinetics of nevirapine during once daily and twice daily dosing in HIV-1-infected individuals. AIDS 14(8), F77-F82 (2000).
    • (2000) AIDS , vol.14 , Issue.8
    • Van Heeswijk, R.P.1    Veldkamp, A.I.2    Mulder, J.W.3
  • 28
    • 73349133044 scopus 로고    scopus 로고
    • In vitro-in vivo correlation for nevirapine extended release tablets
    • Macha S, Yong CL, Darrington T, et al. In vitro-in vivo correlation for nevirapine extended release tablets. Biopharm. Drug Dispos. 30(9), 542-550 (2009).
    • (2009) Biopharm. Drug Dispos. , vol.30 , Issue.9 , pp. 542-550
    • MacHa, S.1    Yong, C.L.2    Darrington, T.3
  • 29
    • 47849093252 scopus 로고    scopus 로고
    • Atripla™-HIV therapy in one pill
    • Julg B, Bogner JR. Atripla™-HIV therapy in one pill. Ther. Clin. Risk Manag. 4(3), 573-577 (2008).
    • (2008) Ther. Clin. Risk Manag. , vol.4 , Issue.3 , pp. 573-577
    • Julg, B.1    Bogner, J.R.2
  • 30
    • 0033576816 scopus 로고    scopus 로고
    • Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team
    • Staszewski S, Morales-Ramirez J, Tashima KT, et al. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team. N. Engl. J. Med. 341(25), 1865-1873 (1999).
    • (1999) N. Engl. J. Med. , vol.341 , Issue.25 , pp. 1865-1873
    • Staszewski, S.1    Morales-Ramirez, J.2    Tashima, K.T.3
  • 31
    • 0035715574 scopus 로고    scopus 로고
    • Virological and immunological responses to a once-A-day antiretroviral regimen with didanosine, lamivudine and efavirenz
    • Maggiolo F, Migliorino M, Maserati R, et al. Virological and immunological responses to a once-a-day antiretroviral regimen with didanosine, lamivudine and efavirenz. Antivir. Ther. 6(4), 249-253 (2001).
    • (2001) Antivir. Ther. , vol.6 , Issue.4 , pp. 249-253
    • Maggiolo, F.1    Migliorino, M.2    Maserati, R.3
  • 32
    • 15744367156 scopus 로고    scopus 로고
    • Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral-therapy-naive patients infected with HIV-1
    • van Leth F, Phanuphak P, Stroes E, et al. Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral-therapy-naive patients infected with HIV-1. PLoS Med. 1(1), e19 (2004).
    • (2004) PLoS Med. , vol.1 , Issue.1
    • Van Leth, F.1    Phanuphak, P.2    Stroes, E.3
  • 33
    • 23044457388 scopus 로고    scopus 로고
    • Are adverse events of nevirapine and efavirenz related to plasma concentrations?
    • Kappelhoff BS, van LF, Robinson PA, et al. Are adverse events of nevirapine and efavirenz related to plasma concentrations? Antivir. Ther. 10(4), 489-498 (2005).
    • (2005) Antivir. Ther. , vol.10 , Issue.4 , pp. 489-498
    • Kappelhoff, B.S.1    Van Lf Robinson, P.A.2
  • 34
    • 17144377479 scopus 로고    scopus 로고
    • The effect of baseline CD4 cell count and HIV-1 viral load on the efficacy and safety of nevirapine or efavirenz-based first-line HAART
    • van Leth F, Andrews S, Grinsztejn B, et al. The effect of baseline CD4 cell count and HIV-1 viral load on the efficacy and safety of nevirapine or efavirenz-based first-line HAART. AIDS 19(5), 463-471 (2005).
    • (2005) AIDS , vol.19 , Issue.5 , pp. 463-471
    • Van Leth, F.1    Andrews, S.2    Grinsztejn, B.3
  • 35
    • 33644759713 scopus 로고    scopus 로고
    • Simplicity and efficacy of a once-daily antiretroviral regimen with didanosine, lamivudine, and efavirenz in naive patients: The VESD study
    • Santos J, Palacios R, Lopez M, et al. Simplicity and efficacy of a once-daily antiretroviral regimen with didanosine, lamivudine, and efavirenz in naive patients: the VESD study. HIV Clin. Trials 6(6), 320-328 (2005).
    • (2005) HIV Clin. Trials , vol.6 , Issue.6 , pp. 320-328
    • Santos, J.1    Palacios, R.2    Lopez, M.3
  • 36
    • 33846442010 scopus 로고    scopus 로고
    • Switching strategies to improve lipid profile and morphologic changes
    • Barragan P, Fisac C, Podzamczer D. Switching strategies to improve lipid profile and morphologic changes. AIDS Rev. 8(4), 191-203 (2006).
    • (2006) AIDS Rev. , vol.8 , Issue.4 , pp. 191-203
    • Barragan, P.1    Fisac, C.2    Podzamczer, D.3
  • 37
    • 79960013341 scopus 로고    scopus 로고
    • Steady state evaluation of two extended release (XR) nevirapine (NVP) tablets 400 mg QD compared with immediate release (IR) NVP tablets 200 mg BID in HIV-1 infected patients
    • San Francisco CA USA, 11-15 September Paper #2879[A1-1310]
    • Quinson A-M, Arasteh K, Plettenberg A, et al. Steady state evaluation of two extended release (XR) nevirapine (NVP) tablets 400 mg QD compared with immediate release (IR) NVP tablets 200 mg BID in HIV-1 infected patients. Presented at: 49th ICAAC. San Francisco, CA, USA, 11-15 September 2009 (Paper #2879[A1-1310]).
    • (2009) 49th ICAAC
    • Quinson, A.-M.1    Arasteh, K.2    Plettenberg, A.3
  • 38
    • 80052465229 scopus 로고    scopus 로고
    • Efficacy and safety of nevirapine extended-release once daily versus nevirapine immediate-release twice-daily in treatment-naive HIV-1-infected patients
    • Gathe J, Andrade-Villanueva J, Santiago S, et al. Efficacy and safety of nevirapine extended-release once daily versus nevirapine immediate-release twice-daily in treatment-naive HIV-1-infected patients. Antivir. Ther. 16(5), 759-769 (2011).
    • (2011) Antivir. Ther. , vol.16 , Issue.5 , pp. 759-769
    • Gathe, J.1    Andrade-Villanueva, J.2    Santiago, S.3
  • 39
    • 81755184517 scopus 로고    scopus 로고
    • Prospective comparison of nevirapine and atazanavir/ritonavir both combined with tenofovir DF/emtricitabine in treatment-naive HIV-1 infected patients: ARTEN study week 48 results
    • Cape Town South Africa, 19-22 July Abstract LBPEB07
    • Soriano V, Koppe S, Mingrone H, et al. Prospective comparison of nevirapine and atazanavir/ritonavir both combined with tenofovir DF/emtricitabine in treatment-naive HIV-1 infected patients: ARTEN study week 48 results. Presented at: 5th IAS Conference on HIV Pathogenesis, Treatment and Prevention. Cape Town, South Africa, 19-22 July 2009 (Abstract LBPEB07) (2010).
    • (2009) 5th IAS Conference on HIV Pathogenesis Treatment and Prevention
    • Soriano, V.1    Koppe, S.2    Mingrone, H.3
  • 40
    • 79959435688 scopus 로고    scopus 로고
    • Nevirapine versus atazanavir/ritonavir, each combined with tenofovir disoproxil fumarate/emtricitabine, in antiretroviral-naive HIV-1 patients: The ARTEN Trial
    • ARTEN investigators
    • Soriano V, Arastéh K, Migrone H, et al. ARTEN investigators. Nevirapine versus atazanavir/ritonavir, each combined with tenofovir disoproxil fumarate/emtricitabine, in antiretroviral-naive HIV-1 patients: the ARTEN Trial. Antivir. Ther. 16(3), 339-348 (2011).
    • (2011) Antivir. Ther. , vol.16 , Issue.3 , pp. 339-348
    • Soriano, V.1    Arastéh, K.2    Migrone, H.3
  • 41
    • 77952981523 scopus 로고    scopus 로고
    • Report from the 5th IAS Conference on HIV Pathogenesis Treatment and Prevention. Nevirapine vs. boosted atazanavir-The ARTEN Study
    • Sax PE. Report from the 5th IAS Conference on HIV Pathogenesis Treatment and Prevention. Nevirapine vs. boosted atazanavir-the ARTEN Study. J. Watch. AIDS Clin. Care 21(10), 80 (2009).
    • (2009) J. Watch. AIDS Clin. Care , vol.21 , Issue.10 , pp. 80
    • Sax, P.E.1
  • 42
    • 2642704250 scopus 로고    scopus 로고
    • Human immunodeficiency virus replication and genotypic resistance in blood and lymph nodes after a year of potent antiretroviral therapy
    • Gunthard HF, Wong JK, Ignacio CC, et al. Human immunodeficiency virus replication and genotypic resistance in blood and lymph nodes after a year of potent antiretroviral therapy. J. Virol. 72(3), 2422-2428 (1998).
    • (1998) J. Virol. , vol.72 , Issue.3 , pp. 2422-2428
    • Gunthard, H.F.1    Wong, J.K.2    Ignacio, C.C.3
  • 43
    • 83455167530 scopus 로고    scopus 로고
    • 24 wk efficacy and safety of transitioning virologically stable HIV-1 patients from IR nevirapine 200 mg BID to nevirapine XR 400 mg QD (TRANxITION)
    • Boston, MA, USA, 12-15 September
    • Arasteh K, Ward D, Plettenberg A, et al. 24 wk efficacy and safety of transitioning virologically stable HIV-1 patients from IR nevirapine 200 mg BID to nevirapine XR 400 mg QD (TRANxITION). Presented at: ICAAC 2010. Boston, MA, USA, 12-15 September 2010.
    • (2010) ICAAC 2010
    • Arasteh, K.1    Ward, D.2    Plettenberg, A.3
  • 44
    • 13844274980 scopus 로고    scopus 로고
    • Intermittent HIV-1 viremia (Blips) and drug resistance in patients receiving HAART
    • Nettles RE, Kieffer TL, Kwon P, et al. Intermittent HIV-1 viremia (Blips) and drug resistance in patients receiving HAART. JAMA 293(7), 817-829 (2005).
    • (2005) JAMA , vol.293 , Issue.7 , pp. 817-829
    • Nettles, R.E.1    Kieffer, T.L.2    Kwon, P.3
  • 45
    • 27444436338 scopus 로고    scopus 로고
    • Intermittent episodes of detectable HIV viremia in patients receiving nonnucleoside reverse-transcriptase inhibitor-based or protease inhibitor-based highly active antiretroviral therapy regimens are equivalent in incidence and prognosis
    • Sungkanuparph S, Overton ET, Seyfried W, Groger RK, Fraser VJ, Powderly WG. Intermittent episodes of detectable HIV viremia in patients receiving nonnucleoside reverse-transcriptase inhibitor-based or protease inhibitor-based highly active antiretroviral therapy regimens are equivalent in incidence and prognosis. Clin. Infect. Dis. 41(9), 1326-1332 (2005).
    • (2005) Clin. Infect. Dis. , vol.41 , Issue.9 , pp. 1326-1332
    • Sungkanuparph, S.1    Overton, E.T.2    Seyfried, W.3    Groger, R.K.4    Fraser, V.J.5    Powderly, W.G.6
  • 46
    • 33747689078 scopus 로고    scopus 로고
    • Persistent low-level viraemia and virological failure in HIV-1-infected patients treated with highly active antiretroviral therapy
    • Sungkanuparph S, Groger RK, Overton ET, Fraser VJ, Powderly WG. Persistent low-level viraemia and virological failure in HIV-1-infected patients treated with highly active antiretroviral therapy. HIV Med. 7(7), 437-441 (2006).
    • (2006) HIV Med. , vol.7 , Issue.7 , pp. 437-441
    • Sungkanuparph, S.1    Groger, R.K.2    Overton, E.T.3    Fraser, V.J.4    Powderly, W.G.5
  • 47
    • 75649110048 scopus 로고    scopus 로고
    • Effect of nevirapine on the steady-state trough concentrations of atazanavir in HIV-infected patients receiving atazanavir/ritonavir
    • Molto J, Deig E, Valle M, et al. Effect of nevirapine on the steady-state trough concentrations of atazanavir in HIV-infected patients receiving atazanavir/ritonavir. Ther. Drug Monit. 32(1), 93-96 (2010).
    • (2010) Ther. Drug Monit. , vol.32 , Issue.1 , pp. 93-96
    • Molto, J.1    Deig, E.2    Valle, M.3
  • 48
    • 0030952479 scopus 로고    scopus 로고
    • Decay characteristics of HIV-1-infected compartments during combination therapy
    • Perelson AS, Essunger P, Cao Y, et al. Decay characteristics of HIV-1-infected compartments during combination therapy. Nature 387(6629), 188-191 (1997).
    • (1997) Nature , vol.387 , Issue.6629 , pp. 188-191
    • Perelson, A.S.1    Essunger, P.2    Cao, Y.3
  • 49
    • 0032750441 scopus 로고    scopus 로고
    • Predictors of optimal virological response to potent antiretroviral therapy
    • Powderly WG, Saag MS, Chapman S, Yu G, Quart B, Clendeninn NJ. Predictors of optimal virological response to potent antiretroviral therapy. AIDS 13(14), 1873-1880 (1999).
    • (1999) AIDS , vol.13 , Issue.14 , pp. 1873-1880
    • Powderly, W.G.1    Saag, M.S.2    Chapman, S.3    Yu, G.4    Quart, B.5    Clendeninn, N.J.6
  • 50
    • 0034115801 scopus 로고    scopus 로고
    • The steady-state pharmacokinetics of nevirapine during once daily and twice daily dosing in HIV-1-infected individuals
    • van Heeswijk RP, Veldkamp AI, Mulder JW, et al. The steady-state pharmacokinetics of nevirapine during once daily and twice daily dosing in HIV-1-infected individuals. AIDS 14(8), F77-F82 (2000).
    • (2000) AIDS , vol.14 , Issue.8
    • Van Heeswijk, R.P.1    Veldkamp, A.I.2    Mulder, J.W.3
  • 51
    • 33751116088 scopus 로고    scopus 로고
    • Cardiovascular risk in patients with HIV infection: Impact of antiretroviral therapy
    • Bergersen BM. Cardiovascular risk in patients with HIV infection: impact of antiretroviral therapy. Drugs 66(15), 1971-1987 (2006).
    • (2006) Drugs , vol.66 , Issue.15 , pp. 1971-1987
    • Bergersen, B.M.1
  • 52
    • 74549150032 scopus 로고    scopus 로고
    • Treatment modification in human immunodeficiency virus-infected individuals starting combination antiretroviral therapy between 2005 and 2008
    • Elzi L, Marzolini C, Furrer H, et al. Treatment modification in human immunodeficiency virus-infected individuals starting combination antiretroviral therapy between 2005 and 2008. Arch. Intern. Med. 170(1), 57-65 (2010).
    • (2010) Arch. Intern. Med. , vol.170 , Issue.1 , pp. 57-65
    • Elzi, L.1    Marzolini, C.2    Furrer, H.3
  • 53
    • 78649299819 scopus 로고    scopus 로고
    • Comparison of 48 week efficacy and safety of 400mg QD nevirapine (NVP) extended release formulation (Viramune XR) versus 200mg BID nevirapine immediate release formulation (Viramune IR) in combination with emtricitabine/tenofovir in antiretroviral (ARV) naive HIV-1 infected patients (VERxVE)
    • Vienna Austria July, 18-23
    • Gathe J, Bogner JR, Santiago S, et al. Comparison of 48 week efficacy and safety of 400mg QD nevirapine (NVP) extended release formulation (Viramune XR) versus 200mg BID nevirapine immediate release formulation (Viramune IR) in combination with emtricitabine/tenofovir in antiretroviral (ARV) naive HIV-1 infected patients (VERxVE). Presented at: 18th International AIDS Society (IAS) Conference. Vienna, Austria, July 18-23 2010.
    • (2010) 18th International AIDS Society (IAS) Conference
    • Gathe, J.1    Bogner, J.R.2    Santiago, S.3
  • 55
    • 33750454570 scopus 로고    scopus 로고
    • DHHS panel on antiretroviral guidelines for adults and adolescents-a working group of the office of AIDS research advisory council (OARAC) January
    • DHHS panel on antiretroviral guidelines for adults and adolescents-a working group of the office of AIDS research advisory council (OARAC). Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents (January 2011). http://aidsinfo.nih.gov/contentfiles/ AdultandAdolescentGL.pdf
    • (2011) Guidelines for the Use of Antiretroviral Agents in HIV-1-infected Adults and Adolescents


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.